Global, regional, and National burden of hepatitis C from 1990 to 2021 and projections until 2030 Authors: Junzhu Bai, Hengliang Lv, Longhao Wang, Shumeng You, Dan Liu, Lilin Wang, Yuanyong Xu, Junfeng Lu, Wenyi Zhang Published: 2025 ABSTRACT BackgroundBurden related to hepatitis C (HCV) has imposed severely globally. The World Health Organization has proposed a resolution to eliminate hepatitis C as a public health threat by 2030. By utilizing data from the Global Burden of Diseases (GBD) 2021, the study aims to explore the burden and prediction of diseases related to HCV globally.MethodsThe GBD 2021 was used to assess the burden related to HCV. We obtained the estimated dataset on total burden related to HCV and three subcategories including acute hepatitis C, chronic hepatitis C including cirrhosis, liver cancer due to HCV from GBD 2021. Age-standardized rate (ASR) and number of incidence, prevalence, deaths and disability-adjusted life years (DALYs) were employed to describe the total burden of HCV and classification. Joinpoint regression was used to analysis diseases trends and Bayesian age cohort analysis was used to predict future burden.ResultsThe estimated age-standardized incidence rate (ASIR) of total burden related to HCV decreased from 173.93 per 100,000 in 1990 to 153.82 per 100,000 in 2021, but the incidence shows a significant increase from 9.41 million in 1990 to 11.64 million in 2021 globally. In 2021, ASR of DALYs, mortality and prevalence were 177.24 per 100,000, 6.10 per 100,000 and 1313.83 per 100,000, respectively; all showed downward trends compared rate in 1990. From 1990 to 2021, three types of HCV-related diseases burden changed at different rates. There were significant differences in HCV burden between the genders, age groups and geographical distribution. The burden of HCV showed relatively higher in lower socio-demographic index (SDI) regions, with an ASIR of 237.32/10,000. Acute hepatitis C was more common in low SDI regions, while cirrhosis and liver cancer due to HCV were more common in high SDI regions. By 2030, global HCV-related liver diseases ASIR is projected to rise to 156.55 per 100,000, the burden related to HCV may still at relatively high level worldwide.ConclusionsOur study highlighted the continued significance of HCV as a global public health issue either in the past and in the near future. It is crucial that HCV prevention and control measures, such as screening, early treatment must be targeted and vigorously implemented to achieve the elimination of hepatitis C.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12879-025-12396-y. Introduction Hepatitis C virus (HCV) has emerged as a major global epidemic, severely impacting liver function and causing significant injuries [1].It is primarily transmitted through infected blood or body fluids, and currently, there is no available vaccine for immunization against HCV. Despite the development of direct-acting antiviral medicines (DAAs) that have the potential to cure HCV, certain regions such as Egypt and Mongolia still struggle with their endemicity [2]. Compared to other infectious diseases, fatalities due to HCV have been steadily increasing over the past 15 years [2, 3]. According to data from the World Health Organization (WHO), the number of deaths caused by HCV reached 242,000 in 2022, with a majority of deaths resulting from chronic conditions like cirrhosis and hepatocellular carcinoma (HCC) [4]. HCV stands as an etiology for acute hepatitis C (AHC) as well as chronic hepatitis C (CHC) including cirrhosis, liver cancer due to HCV. HCV serves as a risk factor for progressive liver diseases and may also contribute to further viral transmission. Approximately 30% (15–45%) of individuals infected with the virus spontaneously clear it within 6 months without requiring any treatment. The remaining 70% (55–85%) will develop CHC infection, with a risk of cirrhosis ranging from 15% to 30% over a period of 20 years [2]. Additionally, after 10 years, there is a possibility of progression to HCC [5]. It is noteworthy that approximately, 37% of deaths from liver cancer are attributable to HCV [6], and an estimated 26% of cirrhosis disability-adjusted life years (DALYs) are directly linked to HCV [7]. Therefore, research on HCV is highly necessary. WHO has launched a campaign to eliminate HCV as a public health threat by 2030 [4]. Currently, studies have not yet predicted the future impact of burden related to HCV. Previous studies on HCV epidemiology have largely focused on country- and region- specific data, there are few relative studies about HCV burden at the global level so far. While prior analyses have examined the global burden and trends of acute hepatitis C from 1990 to 2021 [8], our present study expands this focus to the total hepatitis C-related burden across global, regional, and national levels over the same period, retrieved detailed information on the burden related to HCV subdivided into three types in 204 countries and territories from 1990 to 2021, predicted trends in diseases related to HCV worldwide by 2030. Materials and methods Data source Global Burden of Diseases (GBD) 2021 was published in 2024 with epidemiologic assessments of 371 diseases and injuries from 204 countries and territories. The GBD 2021 analyzed 100,983 data sources—such as vital registration systems, surveys, and disease registries—to evaluate health indicators, including incidence, deaths, prevalence and DALYs. The relevant rates of diseases are expressed using the Age-Standardized Rate (ASR). ASR refers to the number of cases per 100,000 people. All age-adjusted measures in this study were directly extracted from the preprocessed results of the GBD 2021 database. These indicators are calculated by the GBD database via the direct standardization method built into its standardized analytical protocol: using the GBD 2021 global reference population as the standard population, and generating standardized values by weighting age-specific crude rates. This method effectively eliminates the interference of age structure differences on indicators across populations or periods, ensuring the comparability of our study results across regions and time. In this study, the ASR of the incidence (ASIR), mortality (ASMR), prevalence (ASPR), and DALYs (ASDR) are mainly applied. Along with 95% uncertainty intervals (UIs), reflect the uncertainty propagated through each stage of diseases estimation. About the methodology, data inputs, and processing techniques employed in GBD 2021 have been thoroughly documented and published in a multitude of reputable academic journals [9], and previous publications have covered both general methodologies for studying total burden related to HCV, as well as specific methodologies for investigating liver cancer and cirrhosis in relation to HCV [10]. As part of GBD 2021, we estimated the total burden related to hepatitis C resulting from three diseases: acute hepatitis C, chronic hepatitis C including cirrhosis and liver cancer due to hepatitis C, which was sourced from the Global Health Data Exchange (GHDx) query tool (http://ghdx.healthdata.org/gbd-results-tool). Acute hepatitis C mainly encompasses cases of acute liver injury and inflammation caused by recent and short - term (less than 6 months) hepatitis C virus (HCV) infection, in the 11th Revision of the International Classification of Diseases (ICD-11), the corresponding codes include 1E50.2, 1E50.20–1E50.21 [11]. Among cases of chronic hepatitis C including cirrhosis, there are specifically the cases that have developed into cirrhosis and those that have not [12], corresponding to ICD-11 codes 1E51.0, 1E51.00–1E51.05. Liver cancer due to HCV originating from hepatocytes, the ICD-11 code for liver cancer due to HCV is 2C12.02 [13]. A concise overview of the estimation process employed by GBD for assessing total burden related to HCV was provided in supplementary material. Meanwhile, according to the socio-demographic index (SDI) group by GBD, explore the burden of HCV in different economic levels. SDI index is an indicator of social development related to health level, which divided into five different levels according to different average annual income, education level, fertility rate and other comprehensive conditions, the value range is 0–1. The closer it is to 1, the higher the socioeconomic level. Based on the socio-demographic index, GBD grouped global countries into five regions: high, high‐middle, middle, low‐middle and low. Data analysis To address the linearity test in the joinpoint regression framework, we specifically evaluated whether the trend could be adequately captured by a single linear segment (i.e., no significant joinpoints) through a statistical hypothesis testing procedure integrated into the model. The test for linearity is conducted by comparing the fit of a model with no joinpoints (pure linear model) against models with one or more joinpoints using a permutation test. This process involves assessing the null hypothesis that the trend is linear (i.e., no significant joinpoints exist) versus the alternative hypothesis that at least one joinpoint is present, indicating a non-linear trend. The permutation test generates empirical p-values to determine if the addition of joinpoints significantly improves model fit: a non-significant p-value (typically p > 0.05) supports the validity of a linear trend, while a significant p-value suggests the presence of one or more joinpoints and thus a non-linear trend. This step ensures that we rigorously verify whether the observed trends can be simplified to a linear pattern before interpreting APC and AAPC results, particularly when APC equals AAPC, which directly indicates a monotonous linear trend over the entire period. The annual percentage change (APC) and the average annual percentage change (AAPC) were applied to analyze the long-term trends of HCV-related diseases by joinpoint regression analysis. The formula for the Average Annual Percentage Change (AAPC) is: \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$${\text{AAPC = }}\left\{ {{\text{exp }}\left( {\sum {{\text{w}}_{\text{i}}}{{\text{b}}_{\text{i}}}{\text{/}}\sum {{\text{w}}_{\text{i}}}} \right){\text{ - 1}}} \right\}{\text{ * 100}}$$\end{document} In this formula, bi represents the slope coefficient for each segment within the target year range, and wi denotes the duration covered by each segment within that year range. The joinpoint model uses the grid search method to explore the possible connection points, each connection point indicates a significant change in the trend by different regions. APC describes the change in disease trends for each segment of the broken line; AAPC represents the weighted sum of APC of all segments, weighted by the duration of each segment. APC > 0 is the increasing trend, APC < 0 indicates a decreasing trend, APC = 0 indicates a constant trend, and APC = AAPC indicates a monotonously increasing or decreasing trend. For the prediction of the total burden associated with HCV and its subtypes from 2022 to 2030, the Integrated Nested Laplace Approximation (INLA) combined with the Bayesian Age - Period - Cohort (BAPC) model is mainly employed [14]. The BAPC model, implemented via R packages “BAPC” and “INLA” within a Bayesian framework based on the traditional Generalized Linear Model (GLM), uses a five - year age - period - cohort interval [15]. Second - order random walk is set as the prior for relevant parameters to reflect their smooth and continuous changes, providing support for predicting trend data in each period and estimating the disease posterior distribution, thus achieving a reliable prediction of the disease burden trend. The Mean Absolute Percentage Error (MAPE) assesses the BAPC model’s goodness - of - fit by calculating the mean of the ratio of prediction - to - actual - value deviation [16]. Lower MAPE indicates better fit and can measure the model’s accuracy in predicting HCV - related total liver diseases burden. Statistical analysis The incidence, prevalence, DALYs and deaths rate were expressed as the estimate per 100,000 population and its 95% uncertainty intervals (UIs). Consistent with the uncertainty quantification protocol of the GBD study, the 95% UI was generated by the 2.5th and 97.5th percentiles of the ordered estimate values for the Cause of Death Ensemble Modelling (CODEm) process of 1,000 draws. These 1,000 draws refer to 1,000 independent model simulation runs conducted by the CODEm method, which fully incorporate uncertainties from GBD’s input data (such as diverse data sources and underreporting corrections) and model construction. After sorting the 1,000 simulated estimates of each indicator, the values at the 2.5th and 97.5th percentiles are selected as the bounds of the 95% UI, a standard approach in GBD to characterize the reliability of disease burden estimates. The percentage changes in burden related to HCV incident cases from 1990 to 2021 were calculated by the equation: Percentage changes \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$= \frac{\begin{gathered}{\text{Incidence cases in 2021}} \hfill \\{\text{ - Incidence cases in 1990}} \hfill \\ \end{gathered} }{{{\text{Incidence cases in 1990}}}} \times 100\%$$\end{document} All statistical visualizations were executed and performed using R software (version 4.4.1). A significance level of 0.05 was used in this study, which means that probability values below this threshold were considered statistically significant. Results The Temporal distribution of burden related to HCV The incidence of diseases due to HCV shows a significant increase from 9.41 million in 1990 to 11.64 million in 2021 globally. Respectively, Table 1 showed AHC had the highest incidence number (7.01 million, 60.22%) in 2021, followed with CHC including cirrhosis (4.48 million, 38.46%) and liver cancer due to HCV (0.15 million, 1.32%). The estimated ASIR of total burden related to HCV was 153.82 per 100,000 (95% UI: 133.90 to 175.85 per 100,000) in 2021, which has decreased from 173.93 per 100,000 (95% UI: 152.10 to 198.63 per 100,000) in 1990 (Table 1). ASIR, ASPR, ASDR and ASMR of burden related to HCV have decreased to varying degrees globally, while the number of cases has still increased. Both DALYs and deaths of AHC have shown a significant downward trend globally. However, the number of deaths from liver cancer due to HCV has almost doubled from 84,665 to 146,522, causing a burden that cannot be underestimated during study period. As shown in Fig. 1, from 1990 to 2021, incidence changed by different paces of three kinds of diseases related to HCV. According to the ASIR change curve, during the study period, ASIR did not change significantly in liver cancer due to HCV, but continued to decline in AHC and CHC including cirrhosis, also, ASDR, ASMR and ASPR showed similar trend (Figure S1-S3).The most pronounced increase in incidence number was observed of liver cancer due to HCV by 139.33%, followed with AHC and CHC including cirrhosis (24.61% and 20.41%) (Table 1). Table 1The incidence cases and ASIR of diseases related to hepatitis C in 1990 and 202119902021ASIR per 100,00095%UI(lower, upper)Incidence Cases95%UI(lower, upper)ASIR per 100,00095%UI(lower, upper)Incidence Cases95%UI(lower, upper)Global173.93152.10198.639,407,6958,121,40710,756,644153.82175.85133.9011,641,34613,202,80610,131,858typeAHC103.7191.49117.035,625,2884,933,8136,428,41992.64104.6582.137,009,9107,885,7676,182,801cirrhosis68.5556.6981.143,718,0343,088,2754,416,13959.3770.7448.904,477,3745,356,7183,691,726liver cancer1.671.451.9564,37355,67075,3921.822.081.56154,062177,255131,916Socio-demographic indexHigh SDI110.0895.51125.04988,470846,2011,130,03695.41107.6782.781,255,0781,452,4501,061,948High-middle SDI144.39125.90165.351,418,2391,232,6971,615,593111.54127.8297.061,346,6131,551,9051,146,233Middle SDI161.74140.13185.482,817,8972,392,2633,258,956132.85152.57115.412,969,6243,398,3292,558,503Low-middle SDI219.93193.76249.062,671,5122,299,8433,050,874190.13214.62165.803,422,4223,910,9852,969,530Low SDI270.95234.34306.191,504,2231,275,4881,745,471237.32268.58205.432,638,7463,059,6192,236,568regionsAndean Latin America95.6983.35109.0335,91630,82041,63884.3796.1872.8953,51461,55645,856Australasia143.45124.32163.6428,12724,29732,531127.53146.35109.6142,56349,47436,084Caribbean161.08140.23183.0057,01849,25365,752143.99165.02124.2465,95675,65656,612Central Asia339.33295.01384.56278,831240,076317,719363.41413.02315.19350,395398,090304,074Central Europe93.8181.60106.80111,65895,665127,31178.4888.6168.2493,979109,39979,481Central Latin America154.93133.19177.24268,922227,990314,614129.49147.60112.06311,967359,551266,126Central Sub-Saharan Africa435.03375.03499.50252,684215,222292,233372.67428.45319.45485,586555,582415,942East Asia150.38129.18173.021,699,3851,450,4291,983,42595.04109.7181.471,191,3841,383,1491,008,917Eastern Europe142.99122.08164.96299,547256,977343,921169.74196.80145.19305,867355,521257,546Eastern Sub-Saharan Africa285.74247.15326.24536,149454,596623,147247.76282.99214.64946,2391,091, 765809,398High-income Asia Pacific173.63148.93202.07331,864279,381390,909117.76134.73100.45371,919443,956307,831High-income North America82.1470.4595.33235,846200,540273,67482.2294.7470.68338,246391,651286,114North Africa and Middle East281.55247.73317.64883,190770,6591,001,781216.13244.81184.601,278,1561,471,0971,078,405Oceania158.65138.01182.2812,81910,95114,965165.11188.02142.0826,68031,02422,781South Asia151.34130.95173.761,615,2341,378,6921,881,181130.22149.32111.642,110,1352,421,1941,808,683Southeast Asia217.61188.95248.671,102,051941,2961,281,534184.47210.15160.551,164,9381,337,0401,007,215Southern Latin America78.1067.6389.2537,52632,54442,86675.1484.2864.8955,18062,46546,755Southern Sub-Saharan Africa165.41141.84189.7281,42869,51994,283167.64192.52144.35125,080145,998106,761Tropical Latin America185.06156.60214.81274,047229,736322,951161.83187.77137.74358,253422,099301,116Western Europe93.4080.68106.42392,188334,389452,71179.5589.8768.64453,466529,352382,031Western Sub-Saharan Africa361.33311.73416.93873,264736,5781,017,387277.65317.42239.661,511,8431,774,3331,271,361Note: ASIR, age-standardized incidence rate; SDI, socio-demographic index; UI, uncertainty interval; AHC, acute hepatitis C; GBD, Global Burden of Disease Table 1The incidence cases and ASIR of diseases related to hepatitis C in 1990 and 202119902021ASIR per 100,00095%UI(lower, upper)Incidence Cases95%UI(lower, upper)ASIR per 100,00095%UI(lower, upper)Incidence Cases95%UI(lower, upper)Global173.93152.10198.639,407,6958,121,40710,756,644153.82175.85133.9011,641,34613,202,80610,131,858typeAHC103.7191.49117.035,625,2884,933,8136,428,41992.64104.6582.137,009,9107,885,7676,182,801cirrhosis68.5556.6981.143,718,0343,088,2754,416,13959.3770.7448.904,477,3745,356,7183,691,726liver cancer1.671.451.9564,37355,67075,3921.822.081.56154,062177,255131,916Socio-demographic indexHigh SDI110.0895.51125.04988,470846,2011,130,03695.41107.6782.781,255,0781,452,4501,061,948High-middle SDI144.39125.90165.351,418,2391,232,6971,615,593111.54127.8297.061,346,6131,551,9051,146,233Middle SDI161.74140.13185.482,817,8972,392,2633,258,956132.85152.57115.412,969,6243,398,3292,558,503Low-middle SDI219.93193.76249.062,671,5122,299,8433,050,874190.13214.62165.803,422,4223,910,9852,969,530Low SDI270.95234.34306.191,504,2231,275,4881,745,471237.32268.58205.432,638,7463,059,6192,236,568regionsAndean Latin America95.6983.35109.0335,91630,82041,63884.3796.1872.8953,51461,55645,856Australasia143.45124.32163.6428,12724,29732,531127.53146.35109.6142,56349,47436,084Caribbean161.08140.23183.0057,01849,25365,752143.99165.02124.2465,95675,65656,612Central Asia339.33295.01384.56278,831240,076317,719363.41413.02315.19350,395398,090304,074Central Europe93.8181.60106.80111,65895,665127,31178.4888.6168.2493,979109,39979,481Central Latin America154.93133.19177.24268,922227,990314,614129.49147.60112.06311,967359,551266,126Central Sub-Saharan Africa435.03375.03499.50252,684215,222292,233372.67428.45319.45485,586555,582415,942East Asia150.38129.18173.021,699,3851,450,4291,983,42595.04109.7181.471,191,3841,383,1491,008,917Eastern Europe142.99122.08164.96299,547256,977343,921169.74196.80145.19305,867355,521257,546Eastern Sub-Saharan Africa285.74247.15326.24536,149454,596623,147247.76282.99214.64946,2391,091, 765809,398High-income Asia Pacific173.63148.93202.07331,864279,381390,909117.76134.73100.45371,919443,956307,831High-income North America82.1470.4595.33235,846200,540273,67482.2294.7470.68338,246391,651286,114North Africa and Middle East281.55247.73317.64883,190770,6591,001,781216.13244.81184.601,278,1561,471,0971,078,405Oceania158.65138.01182.2812,81910,95114,965165.11188.02142.0826,68031,02422,781South Asia151.34130.95173.761,615,2341,378,6921,881,181130.22149.32111.642,110,1352,421,1941,808,683Southeast Asia217.61188.95248.671,102,051941,2961,281,534184.47210.15160.551,164,9381,337,0401,007,215Southern Latin America78.1067.6389.2537,52632,54442,86675.1484.2864.8955,18062,46546,755Southern Sub-Saharan Africa165.41141.84189.7281,42869,51994,283167.64192.52144.35125,080145,998106,761Tropical Latin America185.06156.60214.81274,047229,736322,951161.83187.77137.74358,253422,099301,116Western Europe93.4080.68106.42392,188334,389452,71179.5589.8768.64453,466529,352382,031Western Sub-Saharan Africa361.33311.73416.93873,264736,5781,017,387277.65317.42239.661,511,8431,774,3331,271,361Note: ASIR, age-standardized incidence rate; SDI, socio-demographic index; UI, uncertainty interval; AHC, acute hepatitis C; GBD, Global Burden of Disease The incidence cases and ASIR of diseases related to hepatitis C in 1990 and 2021 Note: ASIR, age-standardized incidence rate; SDI, socio-demographic index; UI, uncertainty interval; AHC, acute hepatitis C; GBD, Global Burden of Disease Fig. 1Number of incidence cases, ASIR of total burden related to hepatitis C(A), acute hepatitis C (B), chronic hepatitis C including cirrhosis (C) and liver cancer due to hepatitis C (D)from 1990 to 2021 ASIR: age-standardized incidence rate Number of incidence cases, ASIR of total burden related to hepatitis C(A), acute hepatitis C (B), chronic hepatitis C including cirrhosis (C) and liver cancer due to hepatitis C (D)from 1990 to 2021 ASIR: age-standardized incidence rate The population distribution of burden related to HCV The burden of HCV by age-specific and sex in 2021 was shown in Fig. 2. The burden of AHC both high in juvenile and elderly populations, prevalence and DALYs rate of AHC peaked in people under 5 years old in 2021, while the deaths rate is concentrated in the elderly, especially in 65 + years people. However, the burden of CHC including cirrhosis increased with age in both sexes, with mortality peaking in the 95 + population, for 53.59 per 100,000 in males and 29.63 per 100,000 in females. Prevalence and deaths showed similar trends in liver cancer, with prevalence peaking in 85–89 years group in both sexes, for 59.31 per 100,000 in males and 34.23 per 100,000 in females respectively, but deaths rate peaking slightly earlier in males than in females (Fig. 2). Unlike AHC, CHC including cirrhosis, liver cancer due to HCV has a greater burden in males. In 2021, the HCV-related deaths were 0.31 million in males, far more than the 0.21 million in females. Fig. 2Age and sex distribution of ASPR, ASDR and ASMR of acute hepatitis C (A-C), chronic hepatitis C including cirrhosis(D-F), liver cancer due to hepatitis C(G-I) and total burden related to hepatitis C(J-L) at global in 2021 ASPR: age-standardized prevalence rate; ASDR: age-standardized of DALYs rate; DALYs: disability-adjusted life-years; ASMR: age-standardized of mortality rate Age and sex distribution of ASPR, ASDR and ASMR of acute hepatitis C (A-C), chronic hepatitis C including cirrhosis(D-F), liver cancer due to hepatitis C(G-I) and total burden related to hepatitis C(J-L) at global in 2021 ASPR: age-standardized prevalence rate; ASDR: age-standardized of DALYs rate; DALYs: disability-adjusted life-years; ASMR: age-standardized of mortality rate The region distribution of burden related to HCV The burden related HCV varies widely around the world, concentrated in Africa, especially in sub-Saharan Africa, in addition, the burden of HCV was also higher in Asian regions, such as Mongolia (Fig. 3). In 2021, the ASIR, ASDR and ASMR of diseases related to HCV in Central Saharan Africa were 372.67 per 100,000, 517.92 per 100,000 and 17.00 per 100,000, which were higher than global values respectively. The global distribution of AHC and CHC including cirrhosis showed similar situation with total burden related to HCV in general. In contrast, burden of liver cancer due to HCV was relatively higher in high-income areas, among GBD regions, high-income Asia Pacific has the highest ASDR (83.2 per 100,000) in 2021, in addition, ASIR of liver cancer due to HCV also higher in East Asia and Western Europe regions. In addition, in terms of the number of diseases and deaths, in addition to Africa and Southeast Asia, East Asia, high-income North America regions were also at the forefront of GBD regions in 2021(Table 1; Fig. 3). Fig. 3The total burden related to hepatitis C for both sexes in 204 countries and territories in 2021. (A) ASIR; (B) ASPR; (C) ASMR; (D) ASDR ASIR: age-standardized incidence rate; ASPR: age-standardized prevalence rate; ASMR: age-standardized of mortality rate; ASDR: age-standardized of DALYs rate; DALYs: disability-adjusted life-years The total burden related to hepatitis C for both sexes in 204 countries and territories in 2021. (A) ASIR; (B) ASPR; (C) ASMR; (D) ASDR ASIR: age-standardized incidence rate; ASPR: age-standardized prevalence rate; ASMR: age-standardized of mortality rate; ASDR: age-standardized of DALYs rate; DALYs: disability-adjusted life-years The burden related to HCV by different SDI regions Total burden of HCV was concentrated in low and low-middle SDI regions, ASIR, ASDR and ASMR in low and low-middle SDI regions were higher than world average level (Table 1&S2-S4). Similar results were observed for AHC and CHC including cirrhosis, whereas the burden of liver cancer due to HCV was more significant in high SDI regions (2.74/10,000) compared to low SDI regions (1.45/10,000). Joinpoint model showed that a downward trend of total diseases related to HCV during the study period with an AAPC of -0.41 (p < 0.05). It is worth noting that the APC of diseases related to HCV in high SDI regions in 2015–2019 was 0.72 (p < 0.05), APC of middle SDI regions in 2014–2021 was 0.23 (p < 0.05), incidence both showed upward trends. In terms of diseases classification, ASIR of AHC decreased and then increased during the study period with an AAPC of -0.38 (p < 0.05) globally, began to rise slightly from 2015 in most areas expect low-middle SDI regions (Fig. 4). Comparatively, incidence of CHC including cirrhosis showed decreased trend, but APC in high SDI regions between 2015 and 2018 being 0.77, APC in middle SDI regions between 2014 and 2021 was 0.15 (p < 0.05). The ASIR of liver cancer due to HCV has increased most and then decreased globally. In high SDI regions, the increase was obvious before 2000 years, APC was 7.99 (p < 0.05) during 1990 to 1993. Although the global incidence of liver cancer due to HCV showed a downward trend after 2000 years, disease burden increased significantly in global and high SDI regions from 2019 to 2021(Fig. 4). Fig. 4Joinpoint regression analysis ASIR of total burden related to hepatitis C (A), acute hepatitis C (B), chronic hepatitis C including cirrhosis (C) and liver cancer due to hepatitis C (D)from 1990 to 2021, by five SDI regions SDI: socio-demographic index Joinpoint regression analysis ASIR of total burden related to hepatitis C (A), acute hepatitis C (B), chronic hepatitis C including cirrhosis (C) and liver cancer due to hepatitis C (D)from 1990 to 2021, by five SDI regions SDI: socio-demographic index Projection of burden related to HCV trends Using the BAPC model predict the future burden of HCV, as shown in Fig. 5, global trend of total diseases related to HCV is still not optimistic over the next 8 years, the ASIR estimated still increase to 156.55 by 2030. The similar pattern are seen for liver cancer caused by HCV, CHC including cirrhosis and AHC, with ASIR estimated increase to be 2.31, 62.58 and 101.85 respectively by 2030. The rate of deaths and DALYs estimated decrease in diseases related to HCV but number will still increase in both indicators. According to three HCV-related diseases, the number of deaths and DALYs will decrease in AHC but increase in the other two liver diseases. Notably, by 2030, the total burden related to HCV is expected to be higher in males than in females, ASDR in males may change to 10.25, continues to higher than 5.43 in females globally. The predicted incidence number of liver cancer due to HCV was 124,341.24 in males, much higher than the predicted incidence of 87,988.49 in females, the difference between the two sexes gradually increased over time. (Fig. 5&S4-S10). Fig. 5Trends in incidence rates of total burden related to hepatitis C (A), acute hepatitis C (B), chronic hepatitis C including cirrhosis (C) and liver cancer due to hepatitis C (D) from 1990 to 2030 in worldwide by Bayesian age-period-cohort model. Note: Data are derived from Bayesian age-period-cohort model fitting, primarily intended to illustrate variation trends, and may differ from observed values in Fig. 4 Trends in incidence rates of total burden related to hepatitis C (A), acute hepatitis C (B), chronic hepatitis C including cirrhosis (C) and liver cancer due to hepatitis C (D) from 1990 to 2030 in worldwide by Bayesian age-period-cohort model. Note: Data are derived from Bayesian age-period-cohort model fitting, primarily intended to illustrate variation trends, and may differ from observed values in Fig. 4 Discussion The study described and summarized the global burden of HCV. We found that the burden related to HCV remained at high levels from 1990 to 2021. The burden of AHC is concentrated on the elderly and the young, while CHC including cirrhosis and liver cancer are aggravated with age. In terms of regional distribution, Central Sub-Saharan Africa had the highest ASIR, while ASDR was at top in North Africa and Middle East in 2021. Disease projections show that HCV are still on the rise in the 2022–2030 period and still contribute to a large burden of disease globally. The burden of HCV showed slightly decreased trend from 1990 to 2021, during this period the medicine such as IFN alpha, ribavirin were sequentially used to treat HCV [17, 18]. Also, the development of DAAs had a dramatic improvement in HCV therapy [19]. According to a report by the WHO, 7% of the HCV diagnosed population (equivalent to 1.1 million individuals) were initiated on treatment in 2015, with approximately half of them receiving DAAs therapy. This kind of therapy decreased the risk of further development of chronic liver diseases and caused decline trend in HCV-related mortality [20, 21]. However, the existing medical problems, such as the inappropriate use of medical equipment, blood and blood products and drug injection might be the reasons for the high incidence of HCV [19]. Although the prevalence of unsafe injections decreased from 39% to 5% during 2000 to 2010, the situation in regions like Eastern Mediterranean and South-East Asia still occurred frequently [19]. In recent years, studies on HCV infection have shown that high-risk sexual behavior, transmission and prevalence of the virus in people who inject drugs (PWID) have become increasingly important risk factors [22]. The burden of HCV increased with age, which is similar to the results of other studies [23]. This may be due to a lack of screening for HCV antibodies before blood donation in donors prior to 1993 and the accumulation of exposure to risk factors by age [24]. The long-continued infection is a risk factor for severe fibrosis [25], with time goes on, the progression rate in older people is higher than in younger people, this may lead to the particular burden of cirrhosis and liver cancer in the elderly [26]. Therefore, it is crucial to diagnose and treat HCV infection as early as possible to prevent disease progression and the associated complications. In addition, diseases caused by HCV also has a certain incidence in newborns, mainly AHC, this is likely attributed to mother-to-child transmission during pregnancy, childbirth, or breastfeeding [27]. Due to the lack of funding and attention, the detection of HCV in pregnant women and perinatal screening of HCV are far from enough worldwide. HCV burden are typically associated with fewer complications during childhood, however, with prolonged disease duration, fibrosis can progress and lead to the development of severe liver diseases in adulthood [24]. It also suggests to strengthen women attaches great importance to the prevention of HCV screening is important. In terms of gender, we found that the burden of HCV in males was larger than in females at the same ages, which might caused by the different transmission for fibrosis progression in two genders. Estrogen has protective effect on the sustainable development of CLDs, in addition, males also proved to have a higher risk of exposure, such as injecting drug users, sex with multiple partners, and engaged in the medical treatment of exposure to blood and body fluids. Related studies also found that AHC increased in men with human immunodeficiency virus (HIV) who have sex with men (MSM) in some western countries [28, 29], dedicated that traumatic sex behavior caused blood-blood contacts have been seemed as HCV transmission risk factors [23]. BAPC result also show that, from 2023 to 2030, the higher prevalence in men than in women indicates that further research and prevention targeting high-risk populations are still needed. The burden of HCV varied significantly between different countries and territories, this may caused by the differences in medical level, DAAs availability and immune response [30, 31]. The burden of HCV is higher in Sub-Saharan Africa, Central Asia. Asia has the highest burden worldwide, this may caused by the largest population. Notably, Mongolia reported the higher ASIR of HCV in Asia even the whole world, this probably come down to widespread medical infections in the last century [32]. This also demonstrates the importance of standardized medical and HCV virological screening. Used to have higher burden of HCV, China has implemented hepatitis prevention programs such as increased blood screening and the use of antiviral drugs have been effective in reducing the incidence, deaths and DALYs of diseases. This has certain reference value for other low-and middle-income countries. Research showed that there are eight recognized genotypes (1–8) HCV strains based on phylogenetic and sequence analyses of whole viral genomes, genotype 1 was more frequent in most countries, followed with genotype 2 and 3 [29, 33]. The above three genotypes were considered as “epidemic subtypes”, found in high-income countries patients commonly [34, 35], genotypes 2 and 3 were more likely to develop liver cancer [36]. In contrast, limited data is available for the less common genotypes, which are often more prevalent in economically disadvantaged regions where comprehensive virological testing may not be feasible and the impact of DAAs treatment was also limited [34]. HCV subtypes prevalent in more restricted regions during a long period in future different spatial differentiation may caused by the complex HCV genotypes geographic distribution globally [37]. Therefore, continued research on HCV at the molecular level in the future is necessary. Unsafe blood transfusions and infusions remain the main route of HCV transmission in underdeveloped regions and countries [38]. The spread of AHC in low-income areas due to invasive medical practices such as dental visits, contamination of hemodialysis, and violations of disinfection practices remains a concern [3]. Also, the limitations in surveillance and report of middle and low SDI regions caused the major HCV-related burden worldwide. AHC incidence is still increasing in some high-income regions, with a 124% increase in the incidence of hepatitis C in the United States from 2013 to 2020. In recent years, 60% of new infections in developed countries can be attributed to injecting drug users, and most cases are concentrated in people under 30 years old [3], this also suggests that we should be wary of the HCV burden becoming younger trend in the future. The distribution of liver cancer due to HCV in different economic regions of the world is reversed to AHC. Among etiologies of liver cancer in GBD, attributable risk factors of HCC have difference in different SDI regions, compared with other risks, HCV was the main etiology of HCC for high SDI regions [39, 40]. The superposition of multiple risks will enhance the possibility of HCC, the chronic diseases such as obesity and diabetes with high prevalence in developed countries, may increase the risk of CHC including cirrhosis [40, 41]. With the continuous research, using of DAAs therapy found a “treat all” way for patients with HCV at any stage, this has also led to a significant increase in cure rates for people infected with HCV, especially in high SDI regions with advanced medical care. However, previous studies have shown that the incidence of CLDs can be reduced after treatment with DAAs, but there is still a risk of HCC recurrence in patients with cirrhosis who are treated. It also underscores the need for continuous testing and diagnosis of those infected. In all, burden of HCV is not confined to a particular region, the features of the diseases and be taken into account regional medical level, population and economic factors, formulate the corresponding prevention measures. During the last two decades, the scale-up of prevention have made great efforts worldwide. However, we cannot claim that the global burden related to HCV is decreasing, the increasing global number of cases may attribute to the global population change and the aging of people infected [42]. Among the goals set by the WHO is the elimination of viral hepatitis C as a public health threat by 2030, specifically, WHO set the goal of reducing the incidence of HCV infection by 90% and cutting HCV-related mortality by 65% by 203044. According to BAPC projections, there are still difficulties in achieving this goal, mainly due to the serious underfunding of HCV prevention and control worldwide, which is particularly significant in low-income countries, and the high incidence of HCV in high SDI countries among marginalized groups such as PWID and incarcerated persons, social lack attention to this group. Despite better screening and testing methods in high-income areas, treatment and intervention rates after detection are often lower, low- and middle-income countries are even worse [44]. Also, the COVID-19 pandemic in 2020 has led to a decrease willingness to see a doctor, which may affect the progress of HCV elimination to some extent. In light of given the ongoing transmission among MSM, especially during large gay festivals and events along with the growing ease of transportation worldwide, the potential risk of cross-border HCV transmission should not be underestimated [28]. Just like study of Michael Houghton [45], the trend of HCV incidence showed us that an effective vaccine in HCV were need to delivered to reduce the global burden of HCV. In addition, health care workers should also improve the abilities to detect HCV and ensure the feasibility of treatment for patients in low-income countries [46]. Some developed countries provided the screening strategies in line with their national conditions, however, these countries should also be alert to the high incidence of chronic liver diseases caused by aging populations and other combination factors such as alcohol consumption and metabolic dysfunction - associated steatotic liver disease (MASLD). This study used GBD data to describe and predict the global burden related to HCV, but there are some limitations. First, the robustness of GBD estimates depends on the quality and quantity of data used for modeling within the database. Second, some countries lack data collection and statistics on HCV, which may lead to a certain bias in the overall research. Third, due to the hidden nature of the disease, the incidence of HCV may be underestimated worldwide. Conclusion In conclusion, an analysis of the HCV burden using GBD 2021 data shows that HCV remains a significant global public health threat, especially in some low-income regions. The burden of HCV is expected to continue to increase by 2030. Countries and regions should adjust their prevention and control strategies according to their respective economic and medical levels, focus on the prevention and control of HCV diseases and their types, and strive to realize the World Health Organization’s (WHO) resolution to eliminate hepatitis C as soon as possible. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1